Brain News and Research

RSS

The human brain is the center of the human nervous system and is a highly complex organ. Enclosed in the cranium, it has the same general structure as the brains of other mammals, but is over three times as large as the brain of a typical mammal with an equivalent body size.

Heidelberg Ion Radiation Therapy Center established; European patients can benefit from new radiation therapy

A new, innovative form of radiation based on verified scientific facts will be available to patients all over Europe within the next few decades. The official kick-off meeting of the Community project ULICE (Union of LIght Ions Centres in Europe), which the European Union is supporting with nearly 10 million euros, was held in fall 2009 in the Department of Radiooncology and Radiation Therapy of the Heidelberg University Hospital.

30 Oct 2009

New hope for chronic pain sufferers

In an Anglo-Italian study, thirty healthy subjects were invited to look at either their own hand, the experimenter's hand, or an object, while their hand was subjected to laser-induced pain.

30 Oct 2009

Absence of male hormones extends transplanted cell survival, says new study

Trophoblast stem cells (TSCs), cells found in the layer of peripheral embryonic stem cells from which the placenta is formed, are thought to exhibit "immune privilege" that aids cell survivability and is potentially beneficial for cell and gene therapies. Further, the survivability of TSCs has been thought to require the presence of ovarian hormones. However, none of these assumptions has ever been verified.

30 Oct 2009

Research project to improve early diagnosis and treatment of mild traumatic brain injuries

With financial backing from a leading nonprofit supporter of military medical research, medical device manufacturer Neuro Kinetics, Inc. (www.neuro-kinetics.com) said today that it is collaborating with the U.S. Army Aeromedical Research Laboratory (USAARL) at Fort Rucker, Alabama, and three other military medical facilities in a comprehensive research project to improve early diagnosis and treatment of mild traumatic brain injuries (mTBI).

30 Oct 2009

Dr. Heather Greene to receive 2009 C.A.R.E. Pharmacy Award

Eisai Inc. and the Alzheimer's Association announce today that Heather Greene, PharmD is the recipient of the 2009 C.A.R.E. Pharmacy Award.

30 Oct 2009

Thrombolytic therapy can reduce stroke disability if given within the first few hours

Routing stroke patients directly to designated stroke centres - instead of taking them to the nearest hospital - dramatically increased access to a key clot-busting drug that can reduce stroke disability if given within the first few hours of symptoms, researchers report in Stroke: Journal of the American Heart Association.

30 Oct 2009

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.

30 Oct 2009

Studies on fruit-fly may lead to new treatments for sleep-disorders

New research on the fruit-fly brain points to a possible mechanism by which temperature influences the body clock, according to scientists from Queen Mary, University of London.

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

New technology enhancements from Varian Medical Systems, designed to make radiotherapy and radiosurgery treatments faster, more accurate, and easier to plan and deliver, will be on display at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago next week.

29 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

29 Oct 2009

NMT Medical reports financial results for third-quarter 2009; narrows net loss to $0.22 per share

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced financial results for the quarter and nine months ended September 30, 2009.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

The House Judiciary Committee today called upon national experts and stakeholders in the fields of science and sport to better understand the effects of head injuries on players in the National Football League (NFL). Nationally recognized sports physician and neurosurgeon, Julian E. Bailes, M.D. was called to provide expert testimony based on decades of research detailing how repetitive head trauma on the field leads to long-term neurological damage among athletes.

29 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. However, a study in the October Journal of Lipid Research finds that similar statin drugs can have profoundly different effects on brain cells -both beneficial and detrimental.

29 Oct 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

Brain News and Research

Further Reading

Heidelberg Ion Radiation Therapy Center established; European patients can benefit from new radiation therapy

New hope for chronic pain sufferers

Absence of male hormones extends transplanted cell survival, says new study

Research project to improve early diagnosis and treatment of mild traumatic brain injuries

Dr. Heather Greene to receive 2009 C.A.R.E. Pharmacy Award

Thrombolytic therapy can reduce stroke disability if given within the first few hours

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Studies on fruit-fly may lead to new treatments for sleep-disorders

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

World’s first Cesium-131 lung implants performed

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

NMT Medical reports financial results for third-quarter 2009; narrows net loss to $0.22 per share

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Third-quarter 2009 financial results of Antigenics announced

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News